<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48546">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848028</url>
  </required_header>
  <id_info>
    <org_study_id>0741/118</org_study_id>
    <nct_id>NCT01848028</nct_id>
  </id_info>
  <brief_title>PsoBest - The German Psoriasis Registry</brief_title>
  <official_title>Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berufsverband der Deutschen Dermatologen e.V. (BVDD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Dermatologische Gesellschaft e.V. (DDG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AbbVie Deutschland GmbH &amp; Co. KG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen Idec</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer Deutschland GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Serono GmbH (former collaborator)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PsoNet.eu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is
      largely confined to systemic therapy in Germany. Systemic therapy includes conventional
      systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment
      (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic
      treatments has been shown in clinical studies (and is incorporated in international
      guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under
      real-world conditions is still missing. PsoBest, the German registry on the treatment of
      moderate to severe Pso and PsA started in 2008 and documents the long-term course of
      patients being administered any biologic or conventional systemic antipsoriatic drug
      authorized in Germany for the first time.

      Objectives: Observation and analysis of the following outcomes of treatment with systemic
      antipsoriatics:

        1. Effectiveness in clinical practice (&quot;real world&quot;)

        2. Benefits and needs on the patients' side

        3. Effectiveness in a long-term course over years

        4. Optimal maintenance dosages

        5. Safety and side-effects profile under routine conditions

        6. Use in case of and effect on co-morbidity

        7. Reliable predictors of response

        8. Benefit and effectiveness of possible combination therapies or alternating use of
           biologics and systemic therapies

      Methods: The registry evaluates the long-term course of 3,500 patients with Pso and PsA
      treated with systemic antipsoriatics.The registry started for seven treatment arms: Fumaric
      acid, methotrexate, ciclosporin A, efalizumab, etanercept, infliximab and adalimumab. While
      efalizumab was withdrawn from the market, ustekinumab was included after authorization.
      Patients are included at first initiation of a given treatment and will remain in the
      registry for 5 years, regardless of subsequent therapy. Nationwide, dermatologic practices
      and hospital ambulances with expertise in systemic and biologic treatment consecutively
      enrol patients. Follow-ups will be every 3 to 6 months, comprising patient and treatment
      characteristics, clinical parameters, patient-defined benefit, quality of life and adverse
      events. Standardized questionnaires will be addressed to the patient and to the
      dermatologist 12 times at the dermatologic centres. In interim intervals, patients are
      directly contacted another 9 times by mail. PsoBest is member of the ENCePP network of
      psoriasis-registries (www.psonet.eu).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>every 6 month for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate clinical outcome of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>every 3 month for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate disease related quality of life of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse and serious adverse events</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Risk for adverse events and serious adverse events for patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Benefit Index (PBI)</measure>
    <time_frame>every 3 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the patient benefit of conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>EuroQol Questionnaire (EQ-5D)</measure>
    <time_frame>every 3 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate general state of health of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire on Supply Quality in Dermatology (FVQ-d)</measure>
    <time_frame>every 3 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate care characteristics of conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>every 6 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate arthritis severity of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Global Assessment (Skin: PaGAs, Arthritis: PaGAa)</measure>
    <time_frame>every 3 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate global severity of skin and arthritis in patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Physician Global Assessment (Skin: PGAs, Arthritis: PGAa)</measure>
    <time_frame>every 6 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate global severity of skin and arthritis in patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease Activity Score 28 (DAS 28), American College of Rheumatology Score (ACR20), Psoriatic Arthritic Response Criteria (PsARC)</measure>
    <time_frame>every 6 months for 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate arthritis severity of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriatic-arthritis</condition>
  <arm_group>
    <arm_group_label>Fumaric acid ester</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Fumaric acid ester, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efalizumab (withdrawn)</arm_group_label>
    <description>Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <description>Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <description>Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <description>Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab</arm_group_label>
    <description>Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab</arm_group_label>
    <description>Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with plaque-type psoriasis or psoriatic-arthritis starting the first systemic
        treatment with authorized atipsoriatic drugs in Germany.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by
             a dermatologist

          -  age ≥ 18 years

          -  being administered a specific systemic drug for the first time

          -  informed consent to participate

          -  sufficient language skills (German)

        Exclusion criteria:

          -  lack of informed consent

          -  patients being participants of clinical trials at the day of admission to the
             registry (if a patient is included into a clinical trial during the registry
             follow-ups, the patient data will be recorded, but analysed separately)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Augustin, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide group of dermatological centers, hospitals and medical offices</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Augustin, Prof. Dr.</last_name>
      <email>m.augustin@uke.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Augustin, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.psobest.de/</url>
    <description>PsoBest - the German psoriasis registry</description>
  </link>
  <link>
    <url>http://www.cvderm.de</url>
    <description>German Center for Health Services Research in Dermatology</description>
  </link>
  <link>
    <url>http://www.psonet.eu</url>
    <description>PsoNet - the European registry of psoriasis</description>
  </link>
  <link>
    <url>http://www.derma.ch/spec/SDNTT.html</url>
    <description>Swiss Dermatology Network for Targeted Therapies (SDNTT)</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient registry</keyword>
  <keyword>Germany</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>psoriatic-arthritis</keyword>
  <keyword>Efalizumab</keyword>
  <keyword>Psonet</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
